SEC Initiates Formal Investigation Into Vioxx Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Escalation of SEC's "informal inquiry" is "not unexpected," Merck says. Company anticipates a federal judicial panel will rule in several weeks on motions to consolidate Vioxx personal injury and shareholder lawsuits for coordinated pretrial proceedings.
You may also be interested in...
Celebrex, Bextra Documents Requested By SEC
SEC investigation joins ongoing investigations by Department of Justice, state attorneys general and a civil suit issued by the State of Louisiana.
Celebrex, Bextra Documents Requested By SEC
SEC investigation joins ongoing investigations by Department of Justice, state attorneys general and a civil suit issued by the State of Louisiana.
After Vioxx Withdrawal, First Thing For Merck Is Paying The Lawyers
Merck increases reserve for legal defense costs related to Vioxx by $604 mil., bringing the total to $675 mil.; the company has not yet established a reserve to cover potential liability. A hearing to consolidate pretrial motions to a single federal judge is scheduled for Jan. 27.